Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. [electronic resource]
Producer: 20140813Description: 51-5 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- adverse effects
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Consolidation Chemotherapy
- Cyclophosphamide -- adverse effects
- Doxorubicin -- adverse effects
- Female
- Humans
- Induction Chemotherapy
- Lymphoma, Follicular -- drug therapy
- Male
- Medication Adherence
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Prednisone -- adverse effects
- Prognosis
- Risk Factors
- Rituximab
- Treatment Outcome
- Vincristine -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.